£ 280.00
Human Cytomegalovirus (CMV) is a prevalent herpesvirus that infects most people worldwide. While CMV infection is often asymptomatic in healthy individuals, it poses significant health risks to immunocompromised patients, such as those undergoing organ transplantation, and to infants born to infected mothers. CMV infection is a significant cause of morbidity and mortality in these populations, leading to complications like pneumonia, retinitis, gastrointestinal disease, and encephalitis.
Assessment of CMV-specific cellular immunity is vital for controlling viral replication and preventing disease, particularly for recipients of donor transplants. ELISpot assays can be utilized to measure CMV-specific T cell responses by detecting cytokine production in response to viral peptides derived from CMV antigen. These assays can help identify individuals at higher risk of CMV disease by assessing their cellular immune response, thereby guiding antiviral prophylaxis and treatment strategies. Research has demonstrated that robust CMV-specific T cell responses correlate with lower rates of CMV disease post-transplantation, underscoring the importance of immune monitoring in managing CMV infections.
Human Cytomegalovirus (CMV) is a prevalent herpesvirus that infects most people worldwide. While CMV infection is often asymptomatic in healthy individuals, it poses significant health risks to immunocompromised patients, such as those undergoing organ transplantation, and to infants born to infected mothers. CMV infection is a significant cause of morbidity and mortality in these populations, leading to complications like pneumonia, retinitis, gastrointestinal disease, and encephalitis.
Assessment of CMV-specific cellular immunity is vital for controlling viral replication and preventing disease, particularly for recipients of donor transplants. ELISpot assays can be utilized to measure CMV-specific T cell responses by detecting cytokine production in response to viral peptides derived from CMV antigen. These assays can help identify individuals at higher risk of CMV disease by assessing their cellular immune response, thereby guiding antiviral prophylaxis and treatment strategies. Research has demonstrated that robust CMV-specific T cell responses correlate with lower rates of CMV disease post-transplantation, underscoring the importance of immune monitoring in managing CMV infections.
Virax Biolabs develops and provides immunology-profiling solutions, with a focus on T cell diagnostics and immune monitoring. Their offerings include research-use products (e.g., peptide pools, ELISpot/FluoroSpot kits, high-affinity antibodies) as well as custom immunology services (such as recombinant antibody engineering, peptide synthesis and protein sequencing).
Virax Biolabs offers a comprehensive range of products to support immunology research and diagnostic development. Their primary product categories include pathogen-specific peptide pools that enable T cell stimulation and immune-response analysis, ELISpot and FluoroSpot kits designed for measuring cytokine secretion and other immune markers, and high-affinity antibodies suitable for use in assays such as ELISA, flow cytometry, and ELISpot. Together, these products provide researchers with precise tools for profiling immune responses in various disease and vaccine studies.
Virax Biolabs provides a range of custom immunology services to meet the diverse needs of academic and industry clients. These services include recombinant antibody engineering, which involves antigen discovery, sequencing, formatting, and bio-conjugation. They also offer custom peptide synthesis and protein sequencing using advanced mass spectrometry, as well as laboratory services that support ELISA, ELISpot, FluoroSpot, and flow cytometry assays. These custom services are designed to help researchers accelerate discovery and optimize immune-response studies.
Virax Biolabs primarily serves researchers and organizations engaged in immunology, infectious disease, and vaccine development. Their customer base includes academic laboratories, biotechnology companies, and pharmaceutical firms that require high-quality immune-profiling tools and diagnostic support. By providing both off-the-shelf research products and tailored immunology services, Virax Biolabs enables scientists to investigate T cell activity, evaluate vaccine efficacy, and develop new diagnostic platforms.
Virax Biolabs’ headquarters is located at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom. Inquiries can be made through the “Contact” section of their website at viraxbiolabs.com.
Many of Virax Biolabs’ products, including peptide pools and ELISpot kits, are intended for research use in immune-profiling and in-vitro studies. However, the company is also developing in-vitro diagnostic (IVD) platforms and T cell diagnostics for applications such as chronic inflammation and immune exhaustion. The intended use and regulatory status vary by product, so customers should refer to the specific product details or contact the company directly for clarification.
